Research

A collection of the latest research and findings in the respiratory space

Research

Filter by topic:

All Asthma COPD Research Bronchiectasis Lung cancer Obstructive sleep apnoea Housing Smoking Management plans Other conditions Access to primary care Health literacy Poverty Health workforce Social determinants IPF Vaping COVID-19

Phase 2B Study of Inhaled RVT-1601 for Chronic Cough in Idiopathic Pulmonary Fibrosis: A Multicenter, Randomized, Placebo-controlled Study (SCENIC Trial) :

Fernando J. Martinez, Marlies S. Wijsenbeek, Ganesh Raghu, Kevin R. Flaherty, Toby M. Maher, Wim A. Wuyts, Michael Kreuter, Martin Kolb, Daniel C. Chambers, Charles Fogarty, Nesrin Mogulkoc, Ahmet S. Tutuncu, and Luca Richeldi

20 January, 2022

NZ Respiratory Research Review Issue 201

Incidence, prevalence and mortality of idiopathic pulmonary fibrosis in Australia:

Ingrid A. Cox, Petr Otahal, Barbara de Graaff, Tamera J. Corte, Yuben Moodley, Chris Zappala, Ian Glaspole, Peter Hopkins, Sacha Macansh, E. Haydn Walters, Andrew J. Palmer

21 December, 2021

NZ Respiratory Research Review Issue 201

Barriers and facilitators to best care for idiopathic pulmonary fibrosis in Australia:

Gabriella Tikellis, Tamera J. Corte, Alan K.Y. Teoh, Ian N. Glaspole, Sacha Macansh, Anne E. Holland

15 November, 2021

NZ Respiratory Research Review Issue 201

Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial:

Jean-Marc Naccache, MD Prof Stéphane Jouneau, PhD Morgane Didier, MD Raphaël Borie, PhD Marine Cachanado, MSc Prof Arnaud Bourdin, PhD et al.

7 September, 2021

NZ Respiratory Research Review Issue 201

Effect of Antimicrobial Therapy on Respiratory Hospitalization or Death in Adults With Idiopathic Pulmonary Fibrosis - The CleanUP-IPF Randomized Clinical Trial:

Fernando J. Martinez, MD, MS; Eric Yow, MS; Kevin R. Flaherty, MD; et al

11 May, 2021

NZ Respiratory Research Review Issue 189

Incidence and Prognostic Significance of Hypoxemia in Fibrotic Interstitial Lung Disease:

Yet H. Khor, MBBS, PhD Lawrence Gutman, MD Nebal Abu Hussein, MD Kerri A. Johannson, MD Ian N. Glaspole, MBBS, PhD Sabina A. Guler, MD Manuela Funke-Chambour, MD Thomas Geiser, MD Nicole S.L. Goh, MBBS, PhD Christopher J. Ryerson, MD

23 April, 2021

NZ Respiratory Research Review Issue 201

Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial:

Prof Jürgen Behr, MD Prof Antje Prasse, MD Prof Michael Kreuter, MD Johannes Johow, PhD Prof Klaus F Rabe, MD Prof Francesco Bonella, MD et al.

30 March, 2021

NZ Respiratory Research Review Issue 189

Pirfenidone plus inhaled N-acetylcysteine for idiopathic pulmonary fibrosis: a randomised trial:

Susumu Sakamoto, Kensuke Kataoka, Yasuhiro Kondoh, Motoyasu Kato, Masaki Okamoto, Hiroshi Mukae, Masashi Bando, Takafumi Suda, Kazuhiro Yatera, Yoshinori Tanino, Tomoo Kishaba, Noboru Hattori, Yoshio Taguchi, Takefumi Saito, Yasuhiko Nishioka, Kazuyoshi Kuwano, Kazuma Kishi, Naohiko Inase, Shinichi Sasaki, Hajime Takizawa, Takeshi Johkoh, Fumikazu Sakai, Sakae Homma the Diffuse Lung Diseases Research Group of the Ministry of Health, Labour and Welfare, Japan

5 January, 2021

NZ Respiratory Research Review Issue 189

Cause of mortality and sarcopenia in patients with idiopathic pulmonary fibrosis receiving antifibrotic therapy:

Yuzo Suzuki, Yuya Aono, Masato Kono, Hirotsugu Hasegawa, Koushi Yokomura, Hyogo Naoi, Hironao Hozumi, Masato Karayama, Kazuki Furuhashi, Noriyuki Enomoto, Tomoyuki Fujisawa, Yutaro Nakamura, Naoki Inui, Hidenori Nakamura, Takafumi Suda

23 September, 2020

NZ Respiratory Research Review Issue 189

Effectiveness of Proton Pump Inhibitors in Idiopathic Pulmonary Fibrosis - A Population-Based Cohort Study:

Tanja Tran, MSc Deborah Assayag, MD Pierre Ernst, MD Samy Suissa, PhD

31 August, 2020

NZ Respiratory Research Review Issue 189